"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " (NA-PHER2)

July 14, 2020 updated by: Fondazione Michelangelo

"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "

This is a multicenter neoadjuvant trial conducted under the sponsorship and overall trial management of the Fondazione Michelangelo in Italy.

Women with a diagnosis of invasive unilateral non metastatic ER-positive breast cancer expressing HER2 and suitable for neoadjuvant therapy Patients in this study will receive: Trastuzumab+Pertuzumab+Palbociclib with or without Fulvestrant (HPPF)

Trastuzumab 8 mg/kg loading dose IV, then 6 mg/kg IV q.3 wks (repeat for a total of 6 administrations) Pertuzumab 840 mg loading dose IV, then 420 mg IV q. 3 wks (repeat for a total of 6 administrations) Palbociclib 125 mg po q.d. x 21 q. 4 wks (= 1 cycle; repeat for a total of 5 cycles) Fulvestrant will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose (total administrations including the additional one = 6)

The total duration of neoadjuvant palbociclib (5 cycles every 4 weeks) and fulvestrant (5 administrations every 4 weeks plus the additional dose given two weeks after the initial dose) was selected to match as closely as possible the total duration of the six planned 3-weekly administrations of trastuzumab and pertuzumab

Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination reported above

After completion of the neoadjuvant and surgical treatment patients will receive irradiation as locally acceptable.

Patients will also continue to receive systemic drug therapy including chemotherapy (plus standard anti-HER2 treatment until completion of full 1 year if HER2 3+ or neu amplified, i.e. cohorts A and B) and endocrine therapy according to local guidelines at the Investigator's discretion.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a multicenter neoadjuvant trial conducted under the sponsorship and overall trial management of the Fondazione Michelangelo in Italy.

Three cohorts of patients are planned

Patients with ER positive tumors (> 10%) and HER2 3+ or neu amplified Cohort A Trastuzumab+Pertuzumab+Palbociclib+Fulvestrant (HPPF)

Cohort B Trastuzumab+Pertuzumab+Palbociclib (HPP) Allocation to Cohort B will be started after recruitment to Cohort A has been completed

Patients with ER positive tumors (> 10%), PgR positive, HER2 1+/2+ (without amplification) and Ki67 > 20% Cohort C Trastuzumab+Pertuzumab+Palbociclib+Fulvestrant (HPPF)

Trastuzumab 8 mg/kg loading dose IV, then 6 mg/kg IV q.3 wks (repeat for a total of 6 administrations) Pertuzumab 840 mg loading dose IV, then 420 mg IV q. 3 wks (repeat for a total of 6 administrations) Palbociclib 125 mg po q.d. x 21 q. 4 wks (= 1 cycle; repeat for a total of 5 cycles) Fulvestrant will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose (total administrations including the additional one = 6)

The total duration of neoadjuvant palbociclib (5 cycles every 4 weeks) and fulvestrant (5 administrations every 4 weeks plus the additional dose given two weeks after the initial dose) was selected to match as closely as possible the total duration of the six planned 3-weekly administrations of trastuzumab and pertuzumab

Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination reported above

After completion of the neoadjuvant and surgical treatment patients will receive irradiation as locally acceptable.

Patients will also continue to receive systemic drug therapy including chemotherapy (plus standard anti-HER2 treatment until completion of full 1 year if HER2 3+ or neu amplified, i.e. cohorts A and B) and endocrine therapy according to local guidelines at the Investigator's discretion.

Primary objectives:

  • Characterize changes of Ki67 from baseline before therapy and at 2 weeks and at surgery (approximately 22 weeks after start of neoadjuvant therapy with HPPF).
  • Characterize changes in apoptosis from baseline before therapy and at surgery (approximately 22 weeks after start of neoadjuvant therapy with HPPF).
  • Study the tolerability profile of the combination

Secondary objectives:

  • Assess the rate of pathological complete response (pCR) defined as ypT0-ypTis ypN0 at surgery
  • Define the clinical objective response rate at the end of the combination
  • Conduct molecular and clinical analyses to assess the presence of informative markers of benefit in addition to Ki67 and apoptosis

Study Type

Interventional

Enrollment (Actual)

102

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • BO
      • Bologna, BO, Italy, 40138
        • Policlinico Sant'Orsola Malpighi
    • FE
      • Ferrara, FE, Italy, 44124
        • Azienda Ospedaliero Universitaria di Ferrara - Arcispedale S. Anna
    • GE
      • Genova, GE, Italy, 16132
        • IST San Martino
    • MI
      • Milano, MI, Italy, 20141
        • Istituto Europeo di Oncologia
      • Milano, MI, Italy, 20100
        • Ospedale San Raffaele
    • RE
      • Reggio Emilia, RE, Italy, 42123
        • Arcispedale S.Maria Nuova A.O.Reggio Emilia
    • UD
      • Udine, UD, Italy, 33100
        • Ospedale Santa Maria della Misericordia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Female patients aged 18 years or older with tumors suitable for neoadjuvant treatment
  2. Early (> 1.5 cm) or locally advanced untreated breast cancer
  3. Histologically confirmed invasive unilateral breast cancer
  4. HER2 status to be centrally confirmed (HER2 3+ of neu amplified for cohorts A and B; HER2 1+/2+ without amplification for cohort C)
  5. Positive estrogen receptor (ER) > 10% and known progesterone receptor (PgR). Note: PgR assessment must be positive for cohort C
  6. Ki67 > 20% for cohort C
  7. Available paraffin-embedded tumor block taken at diagnostic biopsy for central retrospective confirmation of HER2 and ER eligibility and for assessment of Ki67 value and apoptosis is mandatory
  8. All patients must agree to provide tumor tissues for centralized assessment of KI67 values and apoptosis at the required timelines (2 weeks from starting protocol therapy and at surgery)
  9. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
  10. Written informed consent to participate in the trial (approved by the Institutional Review Board/ Independent Ethics Committee) obtained prior to any study specific screening procedures
  11. Willing and able to comply with the protocol

Exclusion Criteria:

  1. Evidence of bilateral invasive breast cancer or metastatic disease (M1)
  2. Pregnant or lactating women.
  3. Women with childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception
  4. Previous treatment with chemotherapy, hormonal therapy or an investigational drug for any type of malignancy
  5. Previous extensive radiotherapy
  6. Previous investigational treatment for any condition within 4 weeks of registration date
  7. Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol
  8. Previous or concomitant malignancy of any other type that could affect compliance with the protocol or interpretation of results.
  9. Other serious illness or medical condition including: history of documented congestive cardiac failure; angina pectoris requiring anti-anginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension; clinically significant valvular heart disease; high-risk uncontrolled arrhythmias
  10. Baseline left ventricular ejection fraction (LVEF) < 55% by echocardiography or multi-gated scintigraphic scan (MUGA)
  11. QTc (corrected QT interval) >480 msec or a family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP)
  12. Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drugs
  13. Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes mellitus
  14. Current use or anticipated need for food or drugs that are known strong CYP3A4 (cytochrome P450 3A4) inhibitors or inducers
  15. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
  16. Abnormal baseline hematological values:
  17. Abnormal baseline liver function, bilirubin, creatinine and/or INR (international normalized ratio)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Trast-pert-palbo-fulve
Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
Other Names:
  • Herceptin
Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
Other Names:
  • Perjeta
Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
Other Names:
  • Ibrabce
Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
Other Names:
  • Faslodex

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serial measures of Ki67
Time Frame: Participants will be followed for the duration of protocol therapy, an expected average of 26 weeks
Changes in Ki67 scores from baseline before therapy, 2 weeks after and then at surgery
Participants will be followed for the duration of protocol therapy, an expected average of 26 weeks
Serial measures of apoptosis
Time Frame: Participants will be followed for the duration of protocol therapy, an expected average of 26 weeks
Changes in apoptosis biomarker scores from baseline before therapy and at surgery
Participants will be followed for the duration of protocol therapy, an expected average of 26 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pathological complete response (pCR)
Time Frame: at surgery
Assess the rate of pathological complete response (pCR) defined as ypT0-ypTis ypN0 at surgery
at surgery
clinical objective response
Time Frame: Participants will be followed for the duration of medical therapy, an expected average of 24 weeks
Assess the clinical objective response rate after medical therapy
Participants will be followed for the duration of medical therapy, an expected average of 24 weeks
Number of participants with adverse events as a Measure of Safety and Tolerability
Time Frame: Participants will be followed for up to 7 months
Number of participants with Adverse Events and related grade
Participants will be followed for up to 7 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (ACTUAL)

September 1, 2019

Study Completion (ACTUAL)

November 1, 2019

Study Registration Dates

First Submitted

September 19, 2014

First Submitted That Met QC Criteria

August 20, 2015

First Posted (ESTIMATE)

August 21, 2015

Study Record Updates

Last Update Posted (ACTUAL)

July 15, 2020

Last Update Submitted That Met QC Criteria

July 14, 2020

Last Verified

July 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • FM-14-B01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.